Antiangiogenesis drug promising for metastatic colorectal cancer

Lancet. 2003 Jun 7;361(9373):1959. doi: 10.1016/S0140-6736(03)13603-3.
No abstract available

Publication types

  • Congress
  • News

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bevacizumab
  • Cetuximab
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / pathology
  • Endothelial Growth Factors / antagonists & inhibitors
  • ErbB Receptors / antagonists & inhibitors
  • Humans
  • Intercellular Signaling Peptides and Proteins
  • Lymphokines / antagonists & inhibitors
  • Neoplasm Metastasis
  • Organoplatinum Compounds / administration & dosage*
  • Oxaliplatin
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Endothelial Growth Factors
  • Intercellular Signaling Peptides and Proteins
  • Lymphokines
  • Organoplatinum Compounds
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors
  • Oxaliplatin
  • Bevacizumab
  • ErbB Receptors
  • Cetuximab